一般演題1-12D ALL：臨床研究

[OS1-12D-5] 再発難治性急性リンパ性白血病患者におけるイノツズマブ オゾガマイシンの投与サイクル数による治療成績

大西 康¹, Davidi I. Marks², Daniel J. DeAngelo³, Elias Jabbour⁴, Anjali Advani⁵, Susan O'Brien⁶, Tao Wang⁷, Alexander Neuhof⁸, Erik Vandendries⁹, Hagop Kantarjian⁴, Wendy Stock¹⁰, Matthias Stelljes¹¹, Ryand D. Cassaday¹² (1.東北大学病院 血液免疫科, 2.University Hospitals Bristol, Bristol, United Kingdom, 3.Dana-Farber Cancer Institute, Boston, MA, USA, 4.University of Texas MD Anderson Cancer Center, Houston, TX, USA, 5.Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA, 6.University of California, Irvine Medical Center, Orange, CA, USA, 7.Pfizer, Inc, Groton, CT, USA, 8.Pfizer Pharma GmbH, Berlin, Germany, 9.Pfizer, Inc, Cambridge, MA, USA, 10.University of California, Irvine Medical Center, Orange, CA, USA, 11.Universitatsklinikum Munster, Germany, 12.University of Washington School of Medicine, FHCRC, Seattle, WA, USA)